PATIENTS LIVING WITH ALS IN THE US, EU AND JAPAN
NEW PATIENTS DIAGNOSED AND THE NUMBER WHO DIE EVERY YEAR
PERCENT OF ALS CASES ARE FATAL
MEAN YEARS SURVIVAL AFTER SYMPTOM ONSET
NUMBER OF APPROVED DRUGS THAT CURE ALS
TOGETHER WE CAN IMPROVE THE NUMBERS
Groundbreaking approach to treating central nervous system disorders by targeting mitochondrial dysfunction
Based on research by co-founder and CSO, Dr. John Nieland and his team at Aalborg University, Denmark, 2N Pharma has developed novel, orally administered, small molecule therapeutic drug candidates that cross the blood-brain barrier to target mitochondrial dysfunction that has been linked to disease progression in several neurodegenerative diseases. We believe our approach will herald a paradigm shift in the fundamental understanding of the etiology and development of neurodegeneration.
2N Pharma’s development pipeline is based on our drug candidate Mitometin, with initial focus on Amyotrophic Lateral Sclerosis (ALS), However, we have pre-clinical data that strongly indicates that other neurological disorders share the same pathogenic mechanism and can be treated by the same or similar drugs, hence we plan to develop optimised versions of Mitometin for treatment of Amyotrophic Lateral Sclerosis, Frontotemporal Dementia and Parkinson’s Disease.
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s Disease or Motor Neurone Disease (MND) is a rapidly progressive and always fatal neurological disease. It was first diagnosed in 1874 by French neurologist Jean-Martin Charcot but despite more than 140 years of research, there is no cure and no effective treatment available.
A Symbol of Hope
The blue cornflower appears fragile but is very hardy, long lasting, and sprouts in the most challenging locations. That’s why it represents the hope for a cure for so many ALS sufferers. 2N Pharma is on a mission to at long last turn hope into reality for many sufferers and their families.
Creation House Program
2N Pharma is proud to have joined the BioInnovation Institute’s Creation House Program, joining a stable of life science innovators, helping accelerate our research and bring treatments rapidly to market.
The Creation House program is supporting early-stage start-ups, who have achieved proof of concept and a business plan. This 18-months long program is designed to mature companies to a competitive international level and to build a case that is focusing on science, business and attracting funding.
Read the BioInnovation Institute’s news article.
Innovation Fund Denmark has awarded 2N Pharma an Innobooster grant of 80.000 USD that assists us in the preclinical development of a drug for Parkinson’s Disease. This grant enables us to expand the efficacy testing of our novel molecules in pre-clinical models of Parkinson’s Disease.
Innovation Fund Denmark invests in the development of promising, innovative ideas into new solutions that create value and help to solve the challenges of our society.
Find out more about the Innobooster grant.